A mélange of new treatments awaiting approval and a lack of patient support are driving down drug utilization for Gilead's HCV blockbuster, according to a new study.
The PBM dropped 25 more drugs from its formulary.
If the HCV drug's trajectory continues, it could exceed Q1 and 2014 sales forecasts, despite payers' reported unease over price.
The PBM encourages step-therapy to control costs.
Pharma needs to step up its sales pitch, looking beyond a drug's top attributes, to convince payers that their drugs are worth the cost.
AstraZeneca launched a home-delivery program for breast cancer drug Arimidex through PBM Express Scripts.
Pfizer's Lipitor had not yet gone off patent before a trio of Senate healthcare heavyweights was firing off letters to the drugmaker assailing its efforts to conserve Lipitor share through a deal with pharmaceutical benefit managers.
The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.